These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30231744)

  • 41. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.
    Jarow JP; Lemery S; Bugin K; Khozin S; Moscicki R
    Ther Innov Regul Sci; 2016 Nov; 50(6):705-709. PubMed ID: 27917324
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration.
    Kuehn CM
    Biomedicines; 2019 Aug; 7(3):. PubMed ID: 31461892
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective.
    Johnson FR; Zhou M
    Value Health; 2016; 19(6):741-745. PubMed ID: 27712700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Message Appeals on an Instagram Account Promoting Seat Belt Use That Attract Adolescents and Young Adults: Elaboration-Likelihood Perspective Study.
    Zhang N; Drake SA; Ding K
    JMIR Form Res; 2020 Sep; 4(9):e16800. PubMed ID: 32985998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
    Huang SM; Strong JM; Zhang L; Reynolds KS; Nallani S; Temple R; Abraham S; Habet SA; Baweja RK; Burckart GJ; Chung S; Colangelo P; Frucht D; Green MD; Hepp P; Karnaukhova E; Ko HS; Lee JI; Marroum PJ; Norden JM; Qiu W; Rahman A; Sobel S; Stifano T; Thummel K; Wei XX; Yasuda S; Zheng JH; Zhao H; Lesko LJ
    J Clin Pharmacol; 2008 Jun; 48(6):662-70. PubMed ID: 18378963
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Additively manufactured medical products - the FDA perspective.
    Di Prima M; Coburn J; Hwang D; Kelly J; Khairuzzaman A; Ricles L
    3D Print Med; 2016; 2():. PubMed ID: 29974058
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Prescription Drug User Fee Act of 1992. A 5-year experiment for industry and the FDA.
    Shulman SR; Kaitin KI
    Pharmacoeconomics; 1996 Feb; 9(2):121-33. PubMed ID: 10160091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The FDA may not regulate tobacco products as "drugs" or as "medical devices".
    Merrill RA
    Duke Law J; 1998 Apr; 47(6):1071-94. PubMed ID: 10557545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trends in the Mental Health Act Review Tribunals: a Welsh experience 2004-2008.
    Aziz VM
    J Forensic Leg Med; 2009 Oct; 16(7):375-7. PubMed ID: 19733323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
    Ronquillo JG; Zuckerman DM
    Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of toxicological information in drug design.
    Matthews EJ; Benz RD; Contrera JF
    J Mol Graph Model; 2000 Dec; 18(6):605-15. PubMed ID: 11155316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generic Pharmaceutical Association (GPhA) - 2015 CMC Workshop (June 9-10, 2015 - Bethesda, Maryland, USA).
    Komlos D
    Drugs Today (Barc); 2015 Jul; 51(7):429-40. PubMed ID: 26261845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Expanded Access on FDA Regulatory Action and Product Labeling.
    Jarow JP; Moscicki R
    Ther Innov Regul Sci; 2017 Nov; 51(6):787-789. PubMed ID: 30079277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs).
    Avila AM; Bebenek I; Bonzo JA; Bourcier T; Davis Bruno KL; Carlson DB; Dubinion J; Elayan I; Harrouk W; Lee SL; Mendrick DL; Merrill JC; Peretz J; Place E; Saulnier M; Wange RL; Yao J; Zhao D; Brown PC
    Regul Toxicol Pharmacol; 2020 Jul; 114():104662. PubMed ID: 32325112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDA review divisions: performance levels and the impact on drug sponsors.
    Milne CP; Kaitin KI
    Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.